Opus Genetics, Inc.
IRD- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001228627
In the last 90 days, Opus Genetics, Inc. insiders filed 0 open-market purchases and 5 sales; 103 institutions reported holding it in 13F filings for Q2 2026, worth $236.4M in total; no superinvestor holds it.
Q2 2026 vs. Q1 2026
How the institutions holding Opus Genetics, Inc. changed between Q1 2026 and Q2 2026.
All holders in Q2 2026All holders in Q1 2026
| Measure | Q1 2026 | Q2 2026 | Change |
|---|---|---|---|
| Holders | 79 | 103 | +24 |
| Shares | 45.4M | 57.5M | +12.1M (+26.6%) |
| Value | $203.8M | $236.4M | +$32.6M (+16.0%) |
New holders (40)
Institutions that held Opus Genetics, Inc. at the end of Q2 2026 but not at the end of Q1 2026.
Sold out (16)
Institutions that held Opus Genetics, Inc. at the end of Q1 2026 and filed for Q2 2026 without it.
| Institution | Shares, Q1 2026 | Value, Q1 2026 |
|---|---|---|
| Perceptive Advisors LLC | 1,835,842 | $8.35M |
| Farallon Capital Management, L.L.C. | 1,000,000 | $4.55M |
| Ameriprise Financial Inc | 388,491 | $1.77M |
| Voleon Capital Management LP | 143,796 | $654.3K |
| Renaissance Technologies LLC | 73,209 | $333.1K |
| HRT Financial LP | 67,663 | $307.0K |
| Brevan Howard Capital Management LP | 61,313 | $279.0K |
| Omers Administration Corp | 41,600 | $189.3K |
| nVerses Capital, LLC | 28,564 | $130.0K |
| Persistent Asset Partners Ltd | 17,919 | $81.5K |
| Bedel Financial Consulting, Inc. | 15,000 | $68.3K |
| Blair William & Co | 12,466 | $56.7K |
| Sanders Morris Harris LLC | 12,000 | $54.6K |
| Group One Trading, L.P. | 10,594 | $48.2K |
| Reliant Investment Partners, LLC | 10,000 | $45.5K |
| Allworth Financial LP | 5 | $23 |